Physiologically Based Pharmacokinetic Modeling and Simulation in Pediatric Drug Development

Overview

Journal CPT Pharmacometrics Syst Pharmacol

Publisher Wiley

Specialty Pharmacology

Date 2014 Oct 30

PMID 25353188

Citations 77

Authors

A R Maharaj

A N Edginton

Affiliations

Soon will be listed here.

Abstract

Increased regulatory demands for pediatric drug development research have fostered interest in the use of modeling and simulation among industry and academia. Physiologically based pharmacokinetic (PBPK) modeling offers a unique modality to incorporate multiple levels of information to estimate age-specific pharmacokinetics. This tutorial will serve to provide the reader with a basic understanding of the procedural steps to developing a pediatric PBPK model and facilitate a discussion of the advantages and limitations of this modeling technique.

Citing Articles

Model-informed drug discovery and development approaches to inform clinical trial design and regulatory decisions: A primer for the MENA region.

Alasmari M, Albusaysi S, Elhefnawy M, Ali A, Altigani K, Almoslem M Saudi Pharm J. 2024; 32(12):102207.

PMID: 39697476 PMC: 11653594. DOI: 10.1016/j.jsps.2024.102207.

Coupling Pre- and Postnatal Infant Exposures with Physiologically Based Pharmacokinetic Modeling to Predict Cumulative Maternal Levetiracetam Exposure During Breastfeeding.

Suryavanshi S, Wang S, Hajducek D, Hamadeh A, Yeung C, Maglalang P Clin Pharmacokinet. 2024; 63(12):1735-1748.

PMID: 39586935 PMC: 11726907. DOI: 10.1007/s40262-024-01447-3.

Is the GFR-based scaling approach adequate for predicting pediatric renal clearance of drugs with passive tubular reabsorption? Insights from PBPK modeling.

Li S, Ye X, Wang Q, Cheng Z, Liu F, Xie F CPT Pharmacometrics Syst Pharmacol. 2024; 14(1):152-163.

PMID: 39403008 PMC: 11706418. DOI: 10.1002/psp4.13254.

Assessment of Infant Exposure to Antidepressants through Breastfeeding: A Literature Review of Currently Available Approaches.

Arbitman L, Chen S, Kim B, Lee M, Zou P, Doughty B Pharmaceutics. 2024; 16(7).

PMID: 39065544 PMC: 11280233. DOI: 10.3390/pharmaceutics16070847.

Physiologically-based pharmacokinetic modeling of pantoprazole to evaluate the role of CYP2C19 genetic variation and obesity in the pediatric population.

Thompson E, Jeong A, Helfer V, Shakhnovich V, Edginton A, Balevic S CPT Pharmacometrics Syst Pharmacol. 2024; 13(8):1394-1408.

PMID: 38837864 PMC: 11330186. DOI: 10.1002/psp4.13167.

References

Maharaj A, Barrett J, Edginton A . A workflow example of PBPK modeling to support pediatric research and development: case study with lorazepam. AAPS J. 2013; 15(2):455-64. PMC: 3675728. DOI: 10.1208/s12248-013-9451-0. View

Hayton W . Maturation and growth of renal function: dosing renally cleared drugs in children. AAPS PharmSci. 2001; 2(1):E3. PMC: 2750998. DOI: 10.1208/ps020103. View

Jamei M, Dickinson G, Rostami-Hodjegan A . A framework for assessing inter-individual variability in pharmacokinetics using virtual human populations and integrating general knowledge of physical chemistry, biology, anatomy, physiology and genetics: A tale of 'bottom-up' vs 'top-down'.... Drug Metab Pharmacokinet. 2009; 24(1):53-75. DOI: 10.2133/dmpk.24.53. View

Price P, Conolly R, Chaisson C, Gross E, Young J, Mathis E . Modeling interindividual variation in physiological factors used in PBPK models of humans. Crit Rev Toxicol. 2003; 33(5):469-503. View

Willmann S, Hohn K, Edginton A, Sevestre M, Solodenko J, Weiss W . Development of a physiology-based whole-body population model for assessing the influence of individual variability on the pharmacokinetics of drugs. J Pharmacokinet Pharmacodyn. 2007; 34(3):401-31. DOI: 10.1007/s10928-007-9053-5. View

Jiang X, Zhao P, Barrett J, Lesko L, Schmidt S . Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e80. PMC: 3817375. DOI: 10.1038/psp.2013.55. View

Yun Y, Edginton A . Correlation-based prediction of tissue-to-plasma partition coefficients using readily available input parameters. Xenobiotica. 2013; 43(10):839-52. DOI: 10.3109/00498254.2013.770182. View

WEST G, Brown J, Enquist B . The fourth dimension of life: fractal geometry and allometric scaling of organisms. Science. 1999; 284(5420):1677-9. DOI: 10.1126/science.284.5420.1677. View

Yun Y, Cotton C, Edginton A . Development of a decision tree to classify the most accurate tissue-specific tissue to plasma partition coefficient algorithm for a given compound. J Pharmacokinet Pharmacodyn. 2013; 41(1):1-14. DOI: 10.1007/s10928-013-9342-0. View

10.

Bjorkman S . Prediction of drug disposition in infants and children by means of physiologically based pharmacokinetic (PBPK) modelling: theophylline and midazolam as model drugs. Br J Clin Pharmacol. 2005; 59(6):691-704. PMC: 1884855. DOI: 10.1111/j.1365-2125.2004.02225.x. View

11.

Anderson B, Holford N . Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009; 24(1):25-36. DOI: 10.2133/dmpk.24.25. View

12.

Huang W, Lee S, Yu L . Mechanistic approaches to predicting oral drug absorption. AAPS J. 2009; 11(2):217-24. PMC: 2691458. DOI: 10.1208/s12248-009-9098-z. View

13.

Rodgers T, Rowland M . Physiologically based pharmacokinetic modelling 2: predicting the tissue distribution of acids, very weak bases, neutrals and zwitterions. J Pharm Sci. 2006; 95(6):1238-57. DOI: 10.1002/jps.20502. View

14.

McNamara P, Alcorn J . Protein binding predictions in infants. AAPS PharmSci. 2002; 4(1):E4. PMC: 2751289. DOI: 10.1208/ps040104. View

15.

Edginton A, Schmitt W, Willmann S . Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin Pharmacokinet. 2006; 45(10):1013-34. DOI: 10.2165/00003088-200645100-00005. View

16.

Tod M, Jullien V, Pons G . Facilitation of drug evaluation in children by population methods and modelling. Clin Pharmacokinet. 2008; 47(4):231-43. DOI: 10.2165/00003088-200847040-00002. View

17.

Edginton A, Schmitt W, Voith B, Willmann S . A mechanistic approach for the scaling of clearance in children. Clin Pharmacokinet. 2006; 45(7):683-704. DOI: 10.2165/00003088-200645070-00004. View

18.

Jones H, Rowland-Yeo K . Basic concepts in physiologically based pharmacokinetic modeling in drug discovery and development. CPT Pharmacometrics Syst Pharmacol. 2013; 2:e63. PMC: 3828005. DOI: 10.1038/psp.2013.41. View

19.

Edginton A, Theil F, Schmitt W, Willmann S . Whole body physiologically-based pharmacokinetic models: their use in clinical drug development. Expert Opin Drug Metab Toxicol. 2008; 4(9):1143-52. DOI: 10.1517/17425255.4.9.1143. View

20.

Huang S, Abernethy D, Wang Y, Zhao P, Zineh I . The utility of modeling and simulation in drug development and regulatory review. J Pharm Sci. 2013; 102(9):2912-23. DOI: 10.1002/jps.23570. View